Published in Eur J Clin Pharmacol on December 27, 2013
Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood (2015) 1.09
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev (2015) 0.79
Influence of Folate-Related Gene Polymorphisms on High-Dose Methotrexate-Related Toxicity and Prognosis in Turkish Children with Acute Lymphoblastic Leukemia. Turk J Haematol (2016) 0.76
Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. Int J Mol Sci (2016) 0.75
Monitoring and Treatment of Acute Kidney Injury in Children with Acute Lymphoblastic Leukemia After High Dose Methotrexate Chemotherapy. Iran J Pharm Res (2016) 0.75
A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet (1995) 17.27
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab (1998) 5.06
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60
Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta (1977) 2.48
Survival outcome of childhood acute lymphoblastic leukemia in India: a resource-limited perspective of more than 40 years. J Pediatr Hematol Oncol (2011) 2.47
A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab (2000) 2.33
A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol (2000) 2.21
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct (1995) 2.05
Molecular action of methotrexate in inflammatory diseases. Arthritis Res (2002) 2.04
Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst (1996) 1.61
Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med (1996) 1.47
Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem (1990) 1.43
Minimal residual disease in leukaemia patients. Lancet Oncol (2001) 1.43
Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem (1981) 1.32
The cellular pharmacology of methotrexate. Pharmacol Ther (1985) 1.31
Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res (2001) 1.23
Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood (2002) 1.21
DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood (2007) 1.20
Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol (2009) 1.19
Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood (2012) 1.17
Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol (1980) 1.17
Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res (2005) 1.13
The pharmacology of methotrexate. J Am Acad Dermatol (1991) 1.13
Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet (2002) 1.11
Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos (2008) 1.06
Mechanisms of action of methotrexate. Immunopharmacology (2000) 1.05
Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer (2011) 1.05
Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res (2001) 1.04
Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood (2013) 1.04
Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica (2006) 0.96
Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol (2008) 0.95
Human thymidylate synthetase--III. Effects of methotrexate and folate analogs. Biochem Pharmacol (1979) 0.93
Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci U S A (1995) 0.89
MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res (2007) 0.88
Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol (2006) 0.88
Polymorphism G80A in the reduced folate carrier gene and its relationship to survival and risk of relapse in acute lymphoblastic leukemia. J Investig Med (2012) 0.87
Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J (2005) 0.84
DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res (2009) 0.84
Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol (2007) 0.83
Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica (2003) 0.83
Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients. Leuk Lymphoma (2013) 0.80
The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics (2003) 0.79
Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL. Leuk Res (2011) 0.79
Rituximab induced myocardial infarction: A fatal drug reaction. J Cancer Res Ther (2011) 1.32
Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol (2011) 1.12
Docetaxel-induced hand foot syndrome: "No dose is a safe dose". J Pharmacol Pharmacother (2012) 1.03
Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib. Med Oncol (2015) 0.78
Low grade follicular lymphoma with high proliferation index; diagnostic and management issues. Indian J Pathol Microbiol (2013) 0.77
A rare case of congenital Ewing sarcoma/PNET of the scapula. J Pediatr Hematol Oncol (2014) 0.76
Optimal surgical staging in early stage epithelial ovarian cancer: a sorry state. Int J Gynecol Cancer (2010) 0.75
A Polymorphism Located Near PMAIP1/Noxa Gene Influences Susceptibility to Hodgkin Lymphoma Development in South India Asian Pac J Cancer Prev (2017) 0.75
Prescription, Transcription and Administration Errors in Out- Patient Day Care Unit of a Regional Cancer Centre in South India. Asian Pac J Cancer Prev (2016) 0.75